389 related articles for article (PubMed ID: 18096160)
1. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
[TBL] [Abstract][Full Text] [Related]
2. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.
Duan W; Peng Q; Masuda N; Ford E; Tryggestad E; Ladenheim B; Zhao M; Cadet JL; Wong J; Ross CA
Neurobiol Dis; 2008 Jun; 30(3):312-322. PubMed ID: 18403212
[TBL] [Abstract][Full Text] [Related]
3. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.
Simmons DA; Belichenko NP; Yang T; Condon C; Monbureau M; Shamloo M; Jing D; Massa SM; Longo FM
J Neurosci; 2013 Nov; 33(48):18712-27. PubMed ID: 24285878
[TBL] [Abstract][Full Text] [Related]
4. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
[TBL] [Abstract][Full Text] [Related]
5. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
[TBL] [Abstract][Full Text] [Related]
6. An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.
Wang N; Lu XH; Sandoval SV; Yang XW
J Huntingtons Dis; 2013; 2(4):443-51. PubMed ID: 25062731
[TBL] [Abstract][Full Text] [Related]
7. Increased Olfactory Bulb BDNF Expression Does Not Rescue Deficits in Olfactory Neurogenesis in the Huntington's Disease R6/2 Mouse.
Smail S; Bahga D; McDole B; Guthrie K
Chem Senses; 2016 Mar; 41(3):221-32. PubMed ID: 26783111
[TBL] [Abstract][Full Text] [Related]
8. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease.
Decressac M; Wright B; Tyers P; Gaillard A; Barker RA
Exp Neurol; 2010 Nov; 226(1):24-32. PubMed ID: 20673761
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
10. Brain-Derived Neurotrophic Factor Prevents Depressive-Like Behaviors in Early-Symptomatic YAC128 Huntington's Disease Mice.
da Fonsêca VS; da Silva Colla AR; de Paula Nascimento-Castro C; Plácido E; Rosa JM; Farina M; Gil-Mohapel J; Rodrigues ALS; Brocardo PS
Mol Neurobiol; 2018 Sep; 55(9):7201-7215. PubMed ID: 29388082
[TBL] [Abstract][Full Text] [Related]
11. Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.
Wang H; Del Mar N; Deng Y; Reiner A
Neurosci Lett; 2021 Oct; 763():136180. PubMed ID: 34416343
[TBL] [Abstract][Full Text] [Related]
12. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
13. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.
Giampà C; Montagna E; Dato C; Melone MA; Bernardi G; Fusco FR
PLoS One; 2013; 8(5):e64037. PubMed ID: 23700454
[TBL] [Abstract][Full Text] [Related]
14. Exercise attenuates neuropathology and has greater benefit on cognitive than motor deficits in the R6/1 Huntington's disease mouse model.
Harrison DJ; Busse M; Openshaw R; Rosser AE; Dunnett SB; Brooks SP
Exp Neurol; 2013 Oct; 248():457-69. PubMed ID: 23911978
[TBL] [Abstract][Full Text] [Related]
15. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
[TBL] [Abstract][Full Text] [Related]
16. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
Seo H; Kim W; Isacson O
Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
[TBL] [Abstract][Full Text] [Related]
17. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease.
Paldino E; Balducci C; La Vitola P; Artioli L; D'Angelo V; Giampà C; Artuso V; Forloni G; Fusco FR
Mol Neurobiol; 2020 Apr; 57(4):1889-1903. PubMed ID: 31879858
[TBL] [Abstract][Full Text] [Related]
19. Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.
Renoir T; Pang TY; Zajac MS; Chan G; Du X; Leang L; Chevarin C; Lanfumey L; Hannan AJ
Br J Pharmacol; 2012 Mar; 165(5):1375-89. PubMed ID: 21718306
[TBL] [Abstract][Full Text] [Related]
20. PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease.
Cardinale A; Paldino E; Giampà C; Bernardi G; Fusco FR
PLoS One; 2015; 10(8):e0134482. PubMed ID: 26252217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
